Chemical compound
Pharmaceutical compound
Tolvaptan Clinical data Trade names Samsca, Jinarc, Jynarque, others Other names OPC-41061 AHFS /Drugs.com Monograph MedlinePlus a609033 License data Pregnancy Routes of By mouth ATC code Legal status Legal status Pharmacokinetic dataBioavailability Unknown (40% absorbed) Protein binding 99% Metabolism Liver (CYP3A4 -mediated)[ 9] Eliminationhalf-life 12 hours (terminal) Identifiers N -(4-{[(5R )-7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H -1-benzazepin-1-yl]carbonyl}-3-methylphenyl)-2-methylbenzamide
CAS Number PubChem CID IUPHAR/BPS DrugBank ChemSpider UNII KEGG ChEBI ChEMBL CompTox Dashboard (EPA) ECHA InfoCard 100.219.212 Chemical and physical data Formula C 26 H 25 Cl N 2 O 3 Molar mass −1 3D model (JSmol ) InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
Y Key:GYHCTFXIZSNGJT-UHFFFAOYSA-N
Y N Y (what is this?) (verify)
Tolvaptan , sold under the brand nameSamsca among others, is anaquaretic drug that functions as a selective,competitive vasopressin receptor 2 (V2 ) antagonist used to treathyponatremia (low bloodsodium levels) associated withcongestive heart failure ,cirrhosis , and thesyndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan was approved by the U.S.Food and Drug Administration (FDA) on May 19, 2009, and is sold byOtsuka Pharmaceutical Co. under the trade name Samsca.[ 10] [ 11]
The U.S.Food and Drug Administration (FDA) granted tolvaptan afast track designation for clinical trials investigating its use for the treatment ofpolycystic kidney disease .[ 12] orphan drug designation in April 2012, for the treatment of autosomal dominant polycystic kidney disease.[ 13]
Tolvaptan is available as ageneric medication .[ 14] [ 15]
Tolvaptan (Samsca) is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia.[ 16]
Tolvaptan (Jynarque) is indicated for slow kidney-function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).[ 17]
Tolvaptan phosphate is aprodrug of tolvaptan, developed forintravenous administration . Tolvaptan phosphate is converted into the active drug tolvaptan in the human body following administration.[ 18]
The FDA has determined that tolvaptan should not be used for longer than 30 days and should not be used in patients with underlying liver disease because it can cause liver injury, potentially leading to liver failure.[ 19] hyponatremia resulting in fatalosmotic demyelination syndrome .[ 20]
Tolvaptan is a selective vasopressin V2 receptor antagonist.[ 16] [ 17]
Tolvaptan is aracemate , a 1:1 mixture of the following two enantiomers:[ 21]
Enantiomers of tolvaptan R )-TolvaptanCAS number: 331947-66-1 S )-TolvaptanCAS number: 331947-44-5
^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)" .nctr-crs.fda.gov .FDA . Retrieved22 Oct 2023 .^ "Tolvaptan GH (Lupin Australia Pty Limited)" .Therapeutic Goods Administration (TGA) . 14 January 2025. Retrieved20 January 2025 .^ "Samsca 15 mg tablets - Summary of Product Characteristics (SmPC)" .(emc) . Retrieved14 December 2020 .^ "Jinarc 15 mg tablets - Summary of Product Characteristics (SmPC)" .(emc) . 21 April 2020. Retrieved14 December 2020 .^ "Jynarque- tolvaptan kit Jynarque- tolvaptan tablet" .DailyMed . 31 March 2020. Retrieved14 December 2020 .^ "Samsca- tolvaptan tablet" .DailyMed . 26 October 2020. Retrieved14 December 2020 .^ "Samsca EPAR" .European Medicines Agency (EMA). Retrieved14 December 2020 .^ "Jinarc EPAR" .European Medicines Agency (EMA). Retrieved14 December 2020 .^ Shoaf S, Elizari M, Wang Z, et al. (2005)."Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias" .J Cardiovasc Pharmacol Ther .10 (3):165– 71.doi :10.1177/107424840501000304 PMID 16211205 .S2CID 39158242 . ^ "Drug Approval Package: Samsca (Tolvaptan) Tablets NDA #022275" .U.S.Food and Drug Administration (FDA) . 21 July 2009. Retrieved15 August 2020 .^ "Drug Approval Package: Jynarque (tolvaptan)" .U.S.Food and Drug Administration (FDA) . 8 June 2018. Retrieved15 August 2020 .^ "Otsuka Maryland Research Institute, Inc. Granted Fast Track Designation For Tolvaptan In PKD" .Medical News Today . Healthline Media UK Ltd. Retrieved6 December 2018 .^ "Tolvaptan Orphan Drug Designations and Approvals" .U.S.Food and Drug Administration (FDA) . 6 April 2012. Retrieved15 August 2020 .^ "Drugs@FDA: FDA-Approved Drugs" .U.S.Food and Drug Administration (FDA) . Retrieved15 August 2020 .^ "Tolvaptan Accord: Pending EC decision" .European Medicines Agency (EMA)the original on 27 January 2023. Retrieved28 January 2023 .^a b "Samsca- tolvaptan tablet" .DailyMed . 28 May 2019. Retrieved15 August 2020 .^a b "Jynarque- tolvaptan kit Jynarque- tolvaptan tablet" .DailyMed . 31 March 2020. Retrieved15 August 2020 .^ "Otsuka Obtains Approval in Japan for SAMTASU® for I.V. Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema" (Press release). March 28, 2022. RetrievedJune 11, 2022 .^ "U.S. Food and Drug Administration." Samsca (Tolvaptan): Drug Safety Communication. N.p., 30 Apr. 2013. Web. 1 June 2014. <[1] ^ Goodman & Gilman's the pharmacological basis of therapeutics . Brunton, Laurence L, Knollmann, Björn C, Hilal-Dandan, Randa (Thirteenth ed.). New York. 5 December 2017.ISBN 9781259584732 OCLC 994570810 .{{cite book }}: CS1 maint: location missing publisher (link ) CS1 maint: others (link )^ Rote Liste Service GmbH (Hrsg.):Rote Liste 2017 - Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte) . Rote Liste Service GmbH, Frankfurt/Main, 2017, Aufl. 57,ISBN 978-3-946057-10-9 , S. 222. "Tolvaptan" .Drug Information Portal . U.S. National Library of Medicine.
-Tolvaptan_Structural_Formula_V1.svg)
N
Y (what is this?) (verify)-Tolvaptan_Structural_Formula_V1.svg)
-Tolvaptan_Structural_Formula_V1.svg)
